Apogee Therapeutics, Inc. (APGE)

In the past six months, Apogee Therapeutics' stock price has been impacted by several events. In January 2026, positive interim results from the Phase 1b trial of Zumilokibart (APG777) in asthma and analyst coverage contributed positively. Also in January 2026, the Chief Medical Officer sold shares following the exercise of stock options. In December 2025, the stock reached its all-time high. In November 2025, pipeline progress and positive interim Phase 1 results from APG333 contributed to a stock rally. In October 2025, a proposed public offering led to a stock price drop, but the offering closed successfully. In July 2025, despite APG777 meeting its main goal in a mid-stage trial for atopic dermatitis, the stock fell. Overall, APGE stock has shown significant growth.

As a clinical-stage biotechnology company, Apogee Therapeutics, Inc. does not currently have commercialized products or services that are subject to traditional demand seasonality. Demand for its potential future products will be driven by the prevalence of the diseases they aim to treat and the successful navigation of clinical trials and regulatory approvals, rather than seasonal fluctuations.

Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology indications. The company operates within the Healthcare sector and Biotechnology industry, discovering, developing, and potentially commercializing innovative therapies. Apogee's antibody programs target well-established mechanisms of action and incorporate advanced antibody engineering to optimize half-life and other properties. Key product candidates include APG777 (Zumilokibart) for atopic dermatitis, asthma, and eosinophilic esophagitis; APG279 for atopic dermatitis; APG990 for atopic dermatitis; APG333 for asthma and COPD; and APG808 for Type 2 allergic diseases, including COPD.

Apogee Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. Its operations and market presence are concentrated within the United States, particularly in the context of its clinical trials and corporate activities.

Apogee Therapeutics generally holds a positive reputation due to its promising clinical pipeline and analyst endorsements. The company has received a consensus rating of "Strong Buy" or "Moderate Buy" from analysts. However, the company has also experienced periods of market skepticism. Events affecting Apogee Therapeutics' reputation include positive clinical trial results, a stock offering that led to a temporary stock drop, and mixed market reaction to trial data. The company's commitment to developing differentiated biologics and its strong cash position also contribute positively to its reputation.

Apogee Therapeutics (APGE) is primarily owned by institutional investors, holding approximately 87.21% of the stock, with insiders owning about 8.20%, and retail investors holding 4.59%. Major institutional owners include VR Adviser, LLC, Fmr Llc, Wellington Management Group Llp, and BlackRock, Inc. A notable individual owner is Nimish P. Shah, who holds 2.56% of the company.